Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 702

1.

Final analysis from RESONATE: up to 6 years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA.

Am J Hematol. 2019 Sep 11. doi: 10.1002/ajh.25638. [Epub ahead of print]

PMID:
31512258
2.

Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21.

Bhatnagar B, Eisfeld AK, Kohlschmidt J, Mrózek K, Nicolet D, Papaioannou D, Walker CJ, Orwick S, Blachly JS, Kolitz JE, Powell BL, Carroll AJ, Stone RM, Byrd JC, Bloomfield CD.

Leukemia. 2019 Aug 28. doi: 10.1038/s41375-019-0560-3. [Epub ahead of print]

PMID:
31462731
3.

Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.

Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, Byrd JC, O'Brien SM, Dilhuydy MS, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan AA, Mahler M, Salman M, Eckert K, Solman IG, Balasubramanian S, Cheng M, Londhe A, Ninomoto J, Howes A, James DF, Hallek M.

Clin Lymphoma Myeloma Leuk. 2019 Jul 15. pii: S2152-2650(19)30398-2. doi: 10.1016/j.clml.2019.07.004. [Epub ahead of print]

PMID:
31447270
4.

T-cell transcriptional profiling and immunophenotyping uncover LAG3 as a potential significant target of immune modulation in multiple myeloma.

Lucas F, Pennell M, Huang Y, Benson DM, Efebera YA, Chaudhry M, Hughes T, Woyach JA, Byrd JC, Zhang S, Jones D, Guan X, Burd CE, Rosko AE.

Biol Blood Marrow Transplant. 2019 Aug 21. pii: S1083-8791(19)30523-3. doi: 10.1016/j.bbmt.2019.08.009. [Epub ahead of print]

PMID:
31445183
5.

Mutations associated with a 17-gene leukemia stem cell score and its prognostic relevance in the context of the European LeukemiaNet classification for acute myeloid leukemia.

Bill M, Nicolet D, Kohlschmidt J, Walker CJ, Mrózek K, Eisfeld AK, Papaioannou D, Rong-Mullins X, Brannan Z, Kolitz JE, Powell BL, Archer KJ, Dorrance AM, Carroll AJ, Stone RM, Byrd JC, Garzon R, Bloomfield CD; Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology.

Haematologica. 2019 Aug 14. pii: haematol.2019.225003. doi: 10.3324/haematol.2019.225003. [Epub ahead of print]

6.

Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia.

Walker CJ, Kohlschmidt J, Eisfeld AK, Mrózek K, Liyanarachchi S, Song C, Nicolet D, Blachly JS, Bill M, Papaioannou D, Oakes CC, Giacopelli B, Genutis LK, Maharry SE, Orwick S, Archer KJ, Powell BL, Kolitz JE, Uy GL, Wang ES, Carroll AJ, Stone RM, Byrd JC, de la Chapelle A, Bloomfield CD.

Clin Cancer Res. 2019 Aug 2. doi: 10.1158/1078-0432.CCR-19-0725. [Epub ahead of print]

PMID:
31375516
7.

A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia.

Andritsos LA, Byrd JC, Cheverton P, Wu J, Sivina M, Kipps TJ, Burger JA.

Leuk Lymphoma. 2019 Jul 27:1-9. doi: 10.1080/10428194.2019.1643463. [Epub ahead of print]

PMID:
31352850
8.

Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML.

Buelow DR, Pounds SB, Wang YD, Shi L, Li Y, Finkelstein D, Shurtleff S, Neale G, Inaba H, Ribeiro RC, Palumbo R, Garrison D, Orwick SJ, Blachly JS, Kroll K, Byrd JC, Gruber TA, Rubnitz JE, Baker SD.

Clin Transl Sci. 2019 Jul 26. doi: 10.1111/cts.12669. [Epub ahead of print]

PMID:
31350825
9.

Challenges and approaches to implementing master/basket trials in oncology.

Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, Redman MW, Druker BJ, Gandara DR.

Blood Adv. 2019 Jul 23;3(14):2237-2243. doi: 10.1182/bloodadvances.2019031229.

10.

Identifying risk factors for depression and anxiety symptoms in patients with chronic lymphocytic leukemia.

Robbertz AS, Weiss DM, Awan FT, Byrd JC, Rogers KA, Woyach JA.

Support Care Cancer. 2019 Jul 22. doi: 10.1007/s00520-019-04991-y. [Epub ahead of print]

PMID:
31332513
11.

Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.

Lucas F, Rogers KA, Harrington BK, Pan A, Yu L, Breitbach J, Bundschuh R, Goettl VM, Hing ZA, Kanga P, Mantel R, Sampath D, Smith LL, Wasmuth R, White DK, Yan P, Byrd JC, Lapalombella R, Woyach JA.

Clin Cancer Res. 2019 Jul 11. doi: 10.1158/1078-0432.CCR-19-0273. [Epub ahead of print]

PMID:
31296529
12.

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia.

Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC.

Blood. 2019 Aug 22;134(8):688-698. doi: 10.1182/blood.2019000490. Epub 2019 Jul 10.

13.

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.

Byrd JC, Smith S, Wagner-Johnston N, Sharman J, Chen AI, Advani R, Augustson B, Marlton P, Commerford SR, Okrah K, Liu L, Murray E, Penuel E, Ward AF, Flinn IW.

Oncotarget. 2019 Jun 4;10(38):3827-3830. doi: 10.18632/oncotarget.27011. eCollection 2019 Jun 4.

14.

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.

Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM.

Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761.

15.

Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia.

Papaioannou D, Nicolet D, Ozer HG, Mrózek K, Volinia S, Fadda P, Carroll AJ, Kohlschmidt J, Kolitz JE, Wang ES, Stone RM, Byrd JC, Garzon R, Bloomfield CD.

Mol Cancer Ther. 2019 Aug;18(8):1451-1459. doi: 10.1158/1535-7163.MCT-18-1125. Epub 2019 Jun 4.

PMID:
31164409
16.

ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.

Chiang CL, Goswami S, Frissora FW, Xie Z, Yan PS, Bundschuh R, Walker LA, Huang X, Mani R, Mo XM, Baskar S, Rader C, Phelps MA, Marcucci G, Byrd JC, Lee LJ, Muthusamy N.

Blood. 2019 Aug 1;134(5):432-444. doi: 10.1182/blood.2018882290. Epub 2019 May 31.

PMID:
31151986
17.

A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma.

McMichael EL, Benner B, Atwal LS, Courtney NB, Mo X, Davis ME, Campbell AR, Duggan MC, Williams K, Martin K, Levine K, Olaverria Salavaggione GN, Noel T, Ganju A, Uppati S, Paul B, Olencki T, Teknos TN, Savvides P, Tridandapani S, Byrd JC, Caligiuri MA, Liu SV, Carson WE 3rd.

Clin Cancer Res. 2019 Aug 15;25(16):4955-4965. doi: 10.1158/1078-0432.CCR-18-2108. Epub 2019 May 29.

PMID:
31142501
18.

Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.

Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, Kay NE, Shanafelt TD, Rabe KG, Byrd JC, Chanan-Khan AA, Furman RR, Hillmen P, Jones J, Seymour JF, Sharman JP, Ferrante L, Mobasher M, Stark T, Reddy V, Dreiling LK, Bhargava P, Howes A, James DF, Zelenetz AD.

Lancet Haematol. 2019 Jul;6(7):e366-e374. doi: 10.1016/S2352-3026(19)30085-7. Epub 2019 May 17. Erratum in: Lancet Haematol. 2019 Jul;6(7):e348.

PMID:
31109827
19.

Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.

Jeon JY, Zhao Q, Buelow DR, Phelps M, Walker AR, Mims AS, Vasu S, Behbehani G, Blachly J, Blum W, Klisovic RB, Byrd JC, Garzon R, Baker SD, Bhatnagar B.

Invest New Drugs. 2019 May 17. doi: 10.1007/s10637-019-00786-4. [Epub ahead of print]

PMID:
31102119
20.

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.

Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Woyach J, Bibikova E, Charuworn P, Frigault MM, Hamdy A, Izumi R, Linghu B, Patel P, Wang MH, Byrd JC.

Blood Adv. 2019 May 14;3(9):1553-1562. doi: 10.1182/bloodadvances.2018030007.

21.

Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies.

Rogers KA, Mousa L, Zhao Q, Bhat SA, Byrd JC, El Boghdadly Z, Guerrero T, Levine LB, Lucas F, Shindiapina P, Sigmund AM, Sullivan M, Wiczer TE, Woyach JA, Awan FT.

Leukemia. 2019 May 13. doi: 10.1038/s41375-019-0481-1. [Epub ahead of print] No abstract available.

PMID:
31086260
22.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF.

Blood. 2019 Jul 11;134(2):111-122. doi: 10.1182/blood.2018882555. Epub 2019 Apr 25.

PMID:
31023700
23.

Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.

Greene JT, Mani R, Ramaswamy R, Frissora F, Yano M, Zapolnik K, Harrington B, Wasmuth R, Tran M, Mo X, McKenna M, Rangnekar VM, Byrd JC, Bondada S, Muthusamy N.

Blood Adv. 2019 Apr 23;3(8):1255-1266. doi: 10.1182/bloodadvances.2018025973.

24.

Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.

Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, Furman RR, Heffner L, Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC.

Haematologica. 2019 Mar 28. pii: haematol.2018.207068. doi: 10.3324/haematol.2018.207068. [Epub ahead of print]

25.

Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance).

Deshields TL, Dueck AC, Rogers K, Brown JR, Shanafelt T, Mintzer D, Byrd JC.

Leuk Lymphoma. 2019 Mar 27:1-4. doi: 10.1080/10428194.2019.1594218. [Epub ahead of print] No abstract available.

PMID:
30916608
26.

Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells.

Do P, Beckwith KA, Cheney C, Tran M, Beaver L, Griffin BG, Mo X, Liu Y, Lapalombella R, Hertlein E, Muthusamy N, Byrd JC.

J Immunol. 2019 May 1;202(9):2806-2816. doi: 10.4049/jimmunol.1801359. Epub 2019 Mar 25.

PMID:
30910862
27.

Targeting CD20 takes the backseat in CLL.

Byrd JC.

Blood. 2019 Mar 7;133(10):1003-1004. doi: 10.1182/blood-2019-01-892695. No abstract available.

28.

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.

Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR.

Blood. 2019 May 9;133(19):2031-2042. doi: 10.1182/blood-2018-08-870238. Epub 2019 Mar 6.

PMID:
30842083
29.

Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLL.

Thangavadivel S, Byrd JC.

Cancer Discov. 2019 Mar;9(3):320-322. doi: 10.1158/2159-8290.CD-19-0029.

PMID:
30824485
30.

Modulation of immune checkpoint molecule expression in mantle cell lymphoma.

Harrington BK, Wheeler E, Hornbuckle K, Y Shana'ah A, Youssef Y, Smith L, Hassan Ii Q, Klamer B, Zhang X, Long M, Baiocchi RA, Maddocks K, Johnson AJ, Byrd JC, Alinari L.

Leuk Lymphoma. 2019 Mar 1:1-10. doi: 10.1080/10428194.2019.1569231. [Epub ahead of print]

PMID:
30821551
31.

Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia.

Ruppert AS, Yin J, Davidian M, Tsiatis AA, Byrd JC, Woyach JA, Mandrekar SJ.

Ann Oncol. 2019 Apr 1;30(4):542-550. doi: 10.1093/annonc/mdz053.

PMID:
30799502
32.

HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics.

Lai TH, Mitchell S, Wu PJ, Orwick S, Liu C, Ravikrishnan J, Woyach J, Mims A, Plunkett W, Puduvalli VK, Byrd JC, Lapalombella R, Sampath D.

Leuk Lymphoma. 2019 Feb 18:1-4. doi: 10.1080/10428194.2019.1571197. [Epub ahead of print] No abstract available.

PMID:
30773117
33.

Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.

O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA.

Am J Hematol. 2019 May;94(5):554-562. doi: 10.1002/ajh.25436. Epub 2019 Mar 8.

34.

Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.

Paz K, Flynn R, Du J, Tannheimer S, Johnson AJ, Dong S, Stark AK, Okkenhaug K, Panoskaltsis-Mortari A, Sage PT, Sharpe AH, Luznik L, Ritz J, Soiffer RJ, Cutler CS, Koreth J, Antin JH, Miklos DB, MacDonald KP, Hill GR, Maillard I, Serody JS, Murphy WJ, Munn DH, Feser C, Zaiken M, Vanhaesebroeck B, Turka LA, Byrd JC, Blazar BR.

Am J Transplant. 2019 Jun;19(6):1820-1830. doi: 10.1111/ajt.15305. Epub 2019 Mar 19.

PMID:
30748099
35.

Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.

Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS.

Br J Haematol. 2019 Jul;186(1):184-188. doi: 10.1111/bjh.15791. Epub 2019 Feb 10. No abstract available.

PMID:
30740654
36.

Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies.

Burger JA, Cramer P, Barr PM, Dilhuydy MS, Mato A, Byrd JC, Chang S, Graef T, Lin T, Tedeschi A.

Br J Haematol. 2019 Jul;186(1):175-180. doi: 10.1111/bjh.15784. Epub 2019 Feb 10. No abstract available.

PMID:
30739324
37.

Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically.

Mrózek K, Eisfeld AK, Kohlschmidt J, Carroll AJ, Walker CJ, Nicolet D, Blachly JS, Bill M, Papaioannou D, Wang ES, Uy GL, Kolitz JE, Powell BL, Blum W, Stone RM, Byrd JC, Bloomfield CD.

Leukemia. 2019 Jul;33(7):1620-1634. doi: 10.1038/s41375-019-0390-3. Epub 2019 Feb 8.

38.

Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.

McWilliams EM, Lucas CR, Chen T, Harrington BK, Wasmuth R, Campbell A, Rogers KA, Cheney CM, Mo X, Andritsos LA, Awan FT, Woyach J, Carson WE 3rd, Butchar J, Tridandapani S, Hertlein E, Castro CE, Muthusamy N, Byrd JC.

Blood Adv. 2019 Feb 12;3(3):447-460. doi: 10.1182/bloodadvances.2018025684.

39.

Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia.

Mitchell SR, Larkin K, Grieselhuber NR, Lai TH, Cannon M, Orwick S, Sharma P, Asemelash Y, Zhang P, Goettl VM, Beaver L, Mims A, Puduvalli VK, Blachly JS, Lehman A, Harrington B, Henderson S, Breitbach JT, Williams KE, Dong S, Baloglu E, Senapedis W, Kirschner K, Sampath D, Lapalombella R, Byrd JC.

Blood Adv. 2019 Feb 12;3(3):242-255. doi: 10.1182/bloodadvances.2018024182.

40.

Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.

Hughes JH, Phelps MA, Upton RN, Reuter SE, Gao Y, Byrd JC, Grever MR, Hofmeister CC, Marcucci G, Blum W, Blum KA, Foster DJR.

Br J Clin Pharmacol. 2019 May;85(5):924-934. doi: 10.1111/bcp.13873. Epub 2019 Feb 27.

PMID:
30672004
41.

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.

Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2019 Jan;17(1):12-20. doi: 10.6004/jnccn.2019.0002.

PMID:
30659125
42.

How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.

Stephens DM, Byrd JC.

Blood. 2019 Mar 21;133(12):1298-1307. doi: 10.1182/blood-2018-11-846808. Epub 2019 Jan 14. Review.

PMID:
30642919
43.

Illness Perceptions in Chronic Lymphocytic Leukemia: Testing Leventhal's Self-regulatory Model.

Westbrook TD, Morrison EJ, Maddocks KJ, Awan FT, Jones JA, Woyach JA, Johnson AJ, Byrd JC, Andersen BL.

Ann Behav Med. 2019 Aug 16;53(9):839-848. doi: 10.1093/abm/kay093.

PMID:
30590383
44.

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.

Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA.

Br J Haematol. 2019 Feb;184(4):558-569. doi: 10.1111/bjh.15690. Epub 2018 Dec 2.

45.

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC.

N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1.

46.

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.

Wierda WG, Byrd JC, Davids MS, Furman RR, Cheson BD, Barr PM, Eradat H, Heffner L, Zhou L, Verdugo M, Potluri J, Choi M.

Br J Haematol. 2019 Jun;185(5):961-966. doi: 10.1111/bjh.15666. Epub 2018 Nov 27. No abstract available.

47.

PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Dong S, Harrington BK, Hu EY, Greene JT, Lehman AM, Tran M, Wasmuth RL, Long M, Muthusamy N, Brown JR, Johnson AJ, Byrd JC.

J Clin Invest. 2019 Jan 2;129(1):122-136. doi: 10.1172/JCI99386. Epub 2018 Nov 19.

48.

PLK1: a promising and previously unexplored target in double-hit lymphoma.

Hassan QN 2nd, Alinari L, Byrd JC.

J Clin Invest. 2018 Dec 3;128(12):5206-5208. doi: 10.1172/JCI124919. Epub 2018 Nov 5.

49.

Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA.

Walker CJ, Oakes CC, Genutis LK, Giacopelli B, Liyanarachchi S, Nicolet D, Eisfeld AK, Scholz M, Brock P, Kohlschmidt J, Mrózek K, Bill M, Carroll AJ, Kolitz JE, Powell BL, Wang ES, Niederwieser DW, Stone RM, Byrd JC, Schwind S, de la Chapelle A, Bloomfield CD.

Leukemia. 2019 Mar;33(3):771-775. doi: 10.1038/s41375-018-0281-z. Epub 2018 Oct 5. No abstract available.

50.

Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.

Barrientos JC, Burger JA, Byrd JC, Hillmen P, Zhou C, Ninomoto J, James DF, Kipps TJ.

Leuk Lymphoma. 2019 Apr;60(4):1000-1005. doi: 10.1080/10428194.2018.1512710. Epub 2018 Oct 2.

Supplemental Content

Support Center